Company Analysis

Evommune, Inc. (EVMN)

NYSE: EVMN · Pharmaceutical Preparations · Palo Alto, CA · filing with the SEC since 2025
Grade5.5
◀ Past 4.5● Present 6.9▶ Future 5.0
5 est.

Filings

71 filings since 2017 beside 71 insider forms · Non-accelerated filer and smaller reporting company and emerging growth company · read from EDGAR on Nov 13, 2026
Due nextNon-accelerated filer and smaller reporting company and emerging growth company
10-K Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Mar 31, 2027
10-Q Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by May 15, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 43 days after the quarter ended. The proxy statement was last filed Apr 21, 2026.

Filings a yearinsider forms included
7171
20252026

2026 counts to Nov 13, 2026.

SEC letters: 5 in the last 36 months, the newest Apr 22, 2026.
Insider forms 71

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 12, 2026 424B3 Shelf offering
Nov 12, 2026 10-Q Quarterly report Sep 30, 2026
Nov 12, 2026 8-K items 2.02, 7.01, 9.01 Results released; Investor disclosure (Regulation FD) · Current report
Nov 10, 2026 SCHEDULE 13D/A Activist holder update, amended
Nov 5, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report
Nov 4, 2026 424B3 Shelf offering
Nov 4, 2026 8-K items 1.01, 3.02, 7.01, 8.01 Major agreement signed; Shares sold without registration; Investor disclosure (Regulation FD); Other event · Current report
Oct 1, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report
Sep 23, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report
Sep 15, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report
Sep 9, 2026 424B3 Shelf offering
Sep 9, 2026 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report Sep 8, 2026
Aug 14, 2026 SCHEDULE 13G/A Large holder update, amended
Aug 14, 2026 SCHEDULE 13G Large holder notice
Aug 6, 2026 424B3 Shelf offering
Aug 6, 2026 10-Q Quarterly report Jun 30, 2026
Aug 6, 2026 8-K items 2.02, 9.01 Results released · Current report
Jul 30, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report Jul 29, 2026
Jul 16, 2026 SCHEDULE 13G Large holder notice
Jun 29, 2026 424B3 Shelf offering
Jun 29, 2026 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report
Jun 2, 2026 424B3 Shelf offering
Jun 2, 2026 8-K item 5.07 Shareholder vote · Current report
May 7, 2026 424B3 Shelf offering
May 7, 2026 10-Q Quarterly report Mar 31, 2026
May 7, 2026 8-K items 2.02, 7.01 Results released; Investor disclosure (Regulation FD) · Current report
Apr 24, 2026 EFFECT Registration effective
Apr 24, 2026 424B3 Shelf offering
Apr 22, 2026 CORRESP Reply to the SEC
Apr 22, 2026 UPLOAD SEC comment letter
Apr 21, 2026 ARS Annual report to shareholders Dec 31, 2025
Apr 21, 2026 DEFA14A Extra proxy material
Apr 21, 2026 DEF 14A Proxy statement
Apr 17, 2026 S-1 Listing registration
Apr 13, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report
Mar 5, 2026 S-8 Employee stock plan registration
Mar 5, 2026 10-K Annual report Dec 31, 2025
Mar 5, 2026 8-K item 2.02 Results released · Current report
Feb 19, 2026 SCHEDULE 13D/A Activist holder update, amended
Feb 17, 2026 SCHEDULE 13D/A Activist holder update, amended
40 of 71 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton EVMN · research, not advice